Skip to main content
. 2023 Aug 22;11(8):e006944. doi: 10.1136/jitc-2023-006944

Figure 3.

Figure 3

CD8+ T cells are required for vaccine-induced protection and H chain loss. (A–D) Batf3-/- BALB/c mice were immunized i.m./EP with 50 µg CCL3-scFv315 DNA or NaCL and challenged intravenous 14 days later with 2×105 MOPC315.BM.Luc cells. (A, B) Tumor growth was followed by whole body bioluminescence. Representative ventral images are shown. (C) M315 in sera on day 35 (mean±SEM), and (D) survival. (E–H) BALB/c were immunized with CCL3-scFv315 and challenged with MOPC315.BM.Luc 14 days later. From day 12 to day 21, mice were injected every other day with 100 µg of either depleting mAb against CD8 or with isotype control mAb. Thereafter, mice were injected with mAbs once a week for 4 weeks. (E, F) Tumor growth was monitored by whole body imaging, (G) measurement of M315 in sera at day 35 (mean±SEM), and (H) survival. A–D: n=5 mice/group, E–H: n=6–8 mice/group. Statistics: Two-way ANOVA with Bonferroni correction (A, E) Mann-Whitney U test (C, G), Mantel Cox log-rank test (D, H). *p<0.05, ***p<0.001, ****p<0.0001. ANOVA, analysis of variance; ND, not detected; ns, not significant; scFv, single-chain fragment variable.